Anti-Aging Startup Raises $116 Million With Bezos Backing
- Unity Biotechnology gets funding from Fidelity, Arch, Venrock
- Seeks treatments for glaucoma, macular degeneration, arthritis
This article is for subscribers only.
A Silicon Valley drugmaker focused on anti-aging treatments has raised $116 million from investors to support the development of medicines designed to help people stay healthy as they grow older.
Unity Biotechnology said Thursday that it attracted support for the Series B funding round from traditional biotech investors including Fidelity Management & Research Co., Arch Venture Partners, Partner Funds Management and Venrock. The San Francisco-based startup is also backed by Bezos Expeditions, the investment arm of Amazon.com Inc. Chief Executive Officer Jeff Bezos.